<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01317784</url>
  </required_header>
  <id_info>
    <org_study_id>07373710</org_study_id>
    <secondary_id>R01DA030234</secondary_id>
    <nct_id>NCT01317784</nct_id>
  </id_info>
  <brief_title>Behavioral Science Aspects of Rapid Test Acceptance</brief_title>
  <acronym>BSARTA</acronym>
  <official_title>Behavioral Science Aspects of Rapid Test Acceptance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California State University, Long Beach</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>California State University, Long Beach</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The relevance of this research to public health is to make it possible to test for hepatitis
      C and syphilis at point of care so that people will receive their results immediately instead
      of requiring people to wait for at least a week to get their test results. This research will
      make rapid tests for HIV available that can detect HIV infection earlier and are more
      accurate than current tests available in the United States.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This application addresses &quot;Studies to improve access and utilization of HIV counseling and
      testing&quot; for &quot;HIV/AIDS and AIDS-related co-infections&quot; such as &quot;hepatitis C virus (HCV),
      other sexually transmitted infections (STIs)&quot; that are part of PA-07-307 Drug Abuse Aspects
      of HIV/AIDS. The only rapid tests that are approved for use in the US currently are for HIV
      infection. Tests for other conditions such as hepatitis C (HCV) and syphilis are in use in
      other countries. In response to an Opportunity that the CDC published in the Federal
      Register, there are now candidate rapid test kits for HCV and syphilis available for
      experimental use in the US. Different combinations of rapid and standard tests will be
      offered to participants in a four-arm trial to assess which tests are accepted by the
      participants. Only a minority of clients at CBRS who have been offered the rapid test for HIV
      have accepted it. Those who chose rapid HIV tests were more likely to be male, educated, gay,
      young and White. They were less likely to be Black, or injection drug users. The proposed
      study has the potential to have a significant impact upon screening for HIV, syphilis, and
      HCV. Rapid tests have the potential to increase the receipt of test results, particularly
      among groups that are less likely to return for their results using traditional testing. The
      candidate tests are designed for Point of Care (either oral fluid and/or whole blood), and
      thus will require real-time testing, so the trial will be able to evaluate both the accuracy
      of the tests in settings of intended use and their acceptability to potential clients in
      real-world situations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Test choice profile</measure>
    <time_frame>one day (day one of study)</time_frame>
    <description>Which tests do participants choose to receive when bundled in different combinations?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Return for standard test results</measure>
    <time_frame>one week</time_frame>
    <description>Is there a different return for test results rate for the different arms of the study?</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1200</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis B</condition>
  <condition>Syphilis</condition>
  <arm_group>
    <arm_group_label>All tests.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Choose from all 16 possible tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV/HCV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Choice of 10 different HIV and hepatitis C tests in the bundle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV/Syphilis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Choice of 7 different tests for HIV and syphilis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Choice of 4 rapid tests for HIV only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rapid tests for HIV, HCV, HBV, and syphilis</intervention_name>
    <description>Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.</description>
    <arm_group_label>All tests.</arm_group_label>
    <other_name>INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.)</other_name>
    <other_name>Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.)</other_name>
    <other_name>DPP® HIV 1/2 Screen Assay (Chembio, Inc.)</other_name>
    <other_name>OraQuick HCV antibody test (Orasure)</other_name>
    <other_name>DPP® HCV Screen Assay (Chembio, Inc.)</other_name>
    <other_name>DPP® HIV-HCV Screen Assay (Chembio, Inc.)</other_name>
    <other_name>Multiplo Rapid HIV/HCV Antibody Test (MedMira, Inc.)</other_name>
    <other_name>DPP® Syphilis Screen &amp; Confirm Assay (Chembio, Inc.)</other_name>
    <other_name>DPP® HIV-Syphilis Screen Assay (Chembio, Inc.)</other_name>
    <other_name>DPP® HIV-HCV-Syphilis Screen Assay (Chembio, Inc.)</other_name>
    <other_name>Multiplo Rapid HIV/HCV/HBV Antibody Test (MedMira, Inc.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HIV/HCV</intervention_name>
    <description>Choice of 10 different tests for HIV and hepatitis C.</description>
    <arm_group_label>HIV/HCV</arm_group_label>
    <other_name>INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.)</other_name>
    <other_name>Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.)</other_name>
    <other_name>DPP® HIV 1/2 Screen Assay (Chembio, Inc.)</other_name>
    <other_name>OraQuick HCV antibody test (Orasure)</other_name>
    <other_name>DPP® HCV Screen Assay (Chembio, Inc.)</other_name>
    <other_name>DPP® HIV-HCV Screen Assay (Chembio, Inc.)</other_name>
    <other_name>Multiplo Rapid HIV/HCV Antibody Test (MedMira, Inc.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HIV/syphilis</intervention_name>
    <description>Choice of 7 different tests for HIV and syphilis</description>
    <arm_group_label>HIV/Syphilis</arm_group_label>
    <other_name>INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.)</other_name>
    <other_name>Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.)</other_name>
    <other_name>DPP® HIV 1/2 Screen Assay (Chembio, Inc.)</other_name>
    <other_name>DPP® Syphilis Screen &amp; Confirm Assay (Chembio, Inc.)</other_name>
    <other_name>DPP® HIV-Syphilis Screen Assay (Chembio, Inc.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HIV only</intervention_name>
    <description>Choice of 4 different tests for HIV only.</description>
    <arm_group_label>HIV only</arm_group_label>
    <other_name>INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.)</other_name>
    <other_name>Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.)</other_name>
    <other_name>DPP® HIV 1/2 Screen Assay (Chembio, Inc.)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 17 years old

          -  Mentally stable

          -  Sober

          -  Able to understand English or Spanish

          -  At least one good vein for phlebotomy

          -  Member of Behavioral Risk Group
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis G Fisher, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>California State University, Long Beach</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Behavioral Research and Services</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2011</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>California State University, Long Beach</investigator_affiliation>
    <investigator_full_name>Dennis G. Fisher</investigator_full_name>
    <investigator_title>Professor and Director</investigator_title>
  </responsible_party>
  <keyword>diagnosis screening</keyword>
  <keyword>HIV serodiagnosis</keyword>
  <keyword>HCV antibodies</keyword>
  <keyword>serologic tests</keyword>
  <keyword>Bedside testing</keyword>
  <keyword>diagnostic test kits</keyword>
  <keyword>syphilis serodiagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Hepatitis C Antibodies</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 25, 2016</submitted>
    <returned>March 24, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

